Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2016

Open Access 01-12-2016 | Research article

Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda

Authors: Simon Walusimbi, Brendan Kwesiga, Rashmi Rodrigues, Melles Haile, Ayesha de Costa, Lennart Bogg, Achilles Katamba

Published in: BMC Health Services Research | Issue 1/2016

Login to get access

Abstract

Background

Microscopic Observation Drug Susceptibility (MODS) and Xpert MTB/Rif (Xpert) are highly sensitive tests for diagnosis of pulmonary tuberculosis (PTB). This study evaluated the cost effectiveness of utilizing MODS versus Xpert for diagnosis of active pulmonary TB in HIV infected patients in Uganda.

Methods

A decision analysis model comparing MODS versus Xpert for TB diagnosis was used. Costs were estimated by measuring and valuing relevant resources required to perform the MODS and Xpert tests. Diagnostic accuracy data of the tests were obtained from systematic reviews involving HIV infected patients. We calculated base values for unit costs and varied several assumptions to obtain the range estimates. Cost effectiveness was expressed as costs per TB patient diagnosed for each of the two diagnostic strategies. Base case analysis was performed using the base estimates for unit cost and diagnostic accuracy of the tests. Sensitivity analysis was performed using a range of value estimates for resources, prevalence, number of tests and diagnostic accuracy.

Results

The unit cost of MODS was US$ 6.53 versus US$ 12.41 of Xpert. Consumables accounted for 59 % (US$ 3.84 of 6.53) of the unit cost for MODS and 84 % (US$10.37 of 12.41) of the unit cost for Xpert. The cost effectiveness ratio of the algorithm using MODS was US$ 34 per TB patient diagnosed compared to US$ 71 of the algorithm using Xpert. The algorithm using MODS was more cost-effective compared to the algorithm using Xpert for a wide range of different values of accuracy, cost and TB prevalence. The cost (threshold value), where the algorithm using Xpert was optimal over the algorithm using MODS was US$ 5.92.

Conclusions

MODS versus Xpert was more cost-effective for the diagnosis of PTB among HIV patients in our setting. Efforts to scale-up MODS therefore need to be explored. However, since other non-economic factors may still favour the use of Xpert, the current cost of the Xpert cartridge still needs to be reduced further by more than half, in order to make it economically competitive with MODS.
Literature
1.
Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins MD, Aziz MA, Pai M. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(10):664–74.CrossRefPubMed
2.
3.
4.
Pai NP, Pai M. Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline, and unmet needs. Discov Med. 2012;13(68):35–45.PubMed
5.
McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis. 2012;205 Suppl 2:S147–158.CrossRefPubMed
6.
Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;1:CD009593.PubMed
7.
Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005–15.CrossRefPubMedPubMedCentral
8.
Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, Davis JL, Whitelaw A, Nicol MP, Gler MT, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011;8(11):e1001120.CrossRefPubMedPubMedCentral
9.
Abimbola TO, Marston BJ, Date AA, Blandford JM, Sangrujee N, Wiktor SZ. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;60(1):e1–7.CrossRefPubMed
10.
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347.CrossRefPubMedPubMedCentral
11.
Langley I, Lin HH, Egwaga S, Doulla B, Ku CC, Murray M, Cohen T, Squire SB. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. Lancet Global Health. 2014;2(10):e581–591.CrossRefPubMed
12.
Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, Dansereau EA, Graetz N, Barber RM, Brown JC, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005–70.CrossRefPubMedPubMedCentral
13.
Pinto LM, Pai M, Dheda K, Schwartzman K, Menzies D, Steingart KR. Scoring systems using chest radiographic features for the diagnosis of pulmonary tuberculosis in adults: a systematic review. Eur Respir J. 2013;42:480–94.CrossRefPubMed
14.
Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163(9):1009–21.CrossRefPubMed
15.
Schnippel K, Meyer-Rath G, Long L, MacLeod W, Sanne I, Stevens WS, Rosen S. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health. 2012;17(9):1142–51.CrossRefPubMedPubMedCentral
16.
Clouse K, Page-Shipp L, Dansey H, Moatlhodi B, Scott L, Bassett J, Stevens W, Sanne I, Van Rie A. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012;102(10):805–7.CrossRefPubMed
17.
Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, Metcalfe JZ, Mutetwa R. Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial. Open forum infectious diseases. 2014;1(1):ofu038.
18.
Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? Lancet Infect Dis. 2014;14(6):527–32.CrossRefPubMed
19.
Philip Wikman-Jorgensen, Jara Llenas-Garcıa, Michael Hobbins, Jochen Ehmer, Rosa Abellana, Alessandra Queiroga Goncalves, Toma`s Maria Pe´rez-Porcuna, Ascaso C: Microscopic observation drug susceptibility assay for the diagnosis of TB and MDR-TB in HIV-infected patients: a systematic review and meta-analysis. Eur Respir J 2014; in press | DOI: 10.​1183/​0903193600079614​
20.
Leung E, Minion J, Benedetti A, Pai M, D M. Microcolony culture techniques for tuberculosis diagnosis: a systematic review. Int J Tuberc Lung Dis. 2011;16(1):16–23.CrossRefPubMed
21.
22.
Caviedes L, Lee TS, Gilman RH, Sheen P, Spellman E, Lee EH, Berg DE, Montenegro-James S. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. J Clin Microbiol. 2000;38(3):1203–8.PubMedPubMedCentral
23.
Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, Sanchez E, Pinedo Y, Saravia JC, Salazar C, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med. 2006;355(15):1539–50.CrossRefPubMedPubMedCentral
24.
Comina G, Mendoza D, Velazco A, Coronel J, Sheen P, Gilman RH, Moore DAJ, M Z. Development of an automated MODS plate reader to detect early growth of Mycobacterium tuberculosis. J Microsc. 2011;242:325–30.CrossRefPubMed
25.
Chaiyasirinroje B, Aung MN, Moolphate S, Kasetjaroen Y, Rienthong S, Rienthong D, Nampaisan O, Nedsuwan S, Sangchun W, Suriyon N, et al. Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB. Inf Drug Resist. 2012;5:79–86.
26.
27.
28.
Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014, Issue 1. Art. No.: CD009593.doi:10.​1002/​14651858.​CD009593.​pub3.
29.
Bwanga F, Haile M, Joloba ML, Ochom E, Hoffner S. Direct nitrate reductase assay versus microscopic observation drug susceptibility test for rapid detection of MDR-TB in Uganda. PLoS One. 2011;6(5):e19565.CrossRefPubMedPubMedCentral
30.
Russell S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg. 2004;71(2 Suppl):147–55.PubMed
31.
Langley I, Adams E, Doulla B, Squire SB. Operational modelling to guide implementation and scale-up of diagnostic tests within the health system: exploring opportunities for parasitic disease diagnostics based on example application for tuberculosis. Parasitology. 2014;141(14):1795–802.CrossRefPubMed
32.
Sohn H, Minion J, Albert H, Dheda K, Pai M. TB diagnostic tests: how do we figure out their costs? Expert Rev Anti-Infect Ther. 2009;7(6):723–33.CrossRefPubMed
33.
Vincent Zishiri, Salome Charalambous, Maunank R. Shah, Violet Chihota, Liesl Page-Shipp, Gavin J. Churchyard, Christopher J. Hoffmann: Implementing a Large-Scale Systematic Tuberculosis Screening Program in Correctional Facilities in South Africa. Open Forum Infect Dis 2014. Doi: 10.​1093/​ofid/​ofu121.
34.
Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–8.CrossRefPubMed
35.
Wekesa C, Kirenga BJ, Joloba ML, Bwanga F, Katamba A, Kamya MR. Chest X-ray vs. Xpert(R) MTB/RIF assay for the diagnosis of sputum smear-negative tuberculosis in Uganda. Int J Tuberc Lung Dis. 2014;18(2):216–9.CrossRefPubMed
36.
Theron G, Pooran A, Peter J, van Zyl-Smit R, Kumar Mishra H, Meldau R, Calligaro G, Allwood B, Sharma SK, Dawson R, et al. Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Eur Respir J. 2012;40(1):161–8.CrossRefPubMed
37.
38.
Creswell J, Codlin AJ, Andre E, Micek MA, Bedru A, Carter EJ, Yadav RP, Mosneaga A, Rai B, Banu S, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis. 2014;14:2.CrossRefPubMedPubMedCentral
39.
Lukoye D, Adatu F, Musisi K, Kasule GW, Were W, Odeke R, Kalamya JN, Awor A, Date A, Joloba ML. Anti-tuberculosis drug resistance among new and previously treated sputum smear-positive tuberculosis patients in Uganda: results of the first national survey. PLoS One. 2013;8(8):e70763.CrossRefPubMedPubMedCentral
40.
Cox HS, Daniels JF, Muller O, Nicol MP, Cox V, van Cutsem G, Moyo S, De Azevedo V, Hughes J. Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa. Open Forum Infect Dis. 2015;2(1):ofv014.CrossRefPubMedPubMedCentral
41.
Cohen GM, Drain PK, Noubary F, Cloete C, Bassett IV. Diagnostic delays and clinical decision making with centralized Xpert MTB/RIF testing in Durban, South Africa. J Acquir Immune Defic Syndr. 2014;67(3):e88–93.CrossRefPubMedPubMedCentral
42.
Hanrahan CF, Haguma P, Ochom E, Kinera I, Cobelens F, Cattamanchi A, Davis L, Katamba A, Dowdy D. Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis. Open Forum Infect Dis. 2016;3(2):ofw068.CrossRefPubMedPubMedCentral
43.
Theron G, Venter R, Calligaro G, Smith L, Limberis J, Meldau R, Chanda D, Esmail A, Peter J, Dheda K. Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results? Clin Infect Dis. 2016;62(8):995–1001.CrossRefPubMed
44.
Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, Mendelson M. False-positive Xpert(R) MTB/RIF assays in previously treated patients: need for caution in interpreting results. Int J Tuberc Lung Dis. 2014;18(7):876–8.CrossRefPubMed
45.
Kim SJ, Lee SH, Kim IS, Kim HJ, Kim SK, Rieder HL. Risk of occupational tuberculosis in National Tuberculosis Programme laboratories in Korea. Int J Tuberc Lung Dis. 2007;11(2):138–42.PubMed
46.
Alva A, Aquino F, Gilman RH, Olivares C, Requena D, Gutierrez AH, Caviedes L, Coronel J, Larson S, Sheen P, et al. Morphological characterization of Mycobacterium tuberculosis in a MODS culture for an automatic diagnostics through pattern recognition. PLoS One. 2013;8(12):e82809.CrossRefPubMedPubMedCentral
47.
Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/Rif for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J. 2013;42:708–20. 2012.CrossRefPubMed
48.
Lin HH, Dowdy D, Dye C, Murray M, Cohen T. The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ. 2012;90(10):739–747A.CrossRefPubMedPubMedCentral
49.
Abebe G, Deribew A, Apers L, Abdissa A, Kiflie Y, Koole O, Colebunders R. Evaluation of the 2007 WHO guideline to diagnose smear negative tuberculosis in an urban hospital in Ethiopia. BMC Infect Dis. 2013;13:427.CrossRefPubMedPubMedCentral
50.
Huerga H, Varaine F, Okwaro E, Bastard M, Ardizzoni E, Sitienei J, Chakaya J, M B. Performance of the 2007 WHO algorithm to diagnose smear-negative pulmonary tuberculosis in a HIV prevalent setting. PLoS One. 2012;7(12):e51336.CrossRefPubMedPubMedCentral
51.
Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, Metcalfe JZ, Mutetwa R. Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial. Open Forum Infect Dis. 2014;1(1):ofu038.CrossRefPubMedPubMedCentral
52.
Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383(9915):424–35.CrossRefPubMed
Metadata
Title
Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda
Authors
Simon Walusimbi
Brendan Kwesiga
Rashmi Rodrigues
Melles Haile
Ayesha de Costa
Lennart Bogg
Achilles Katamba
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2016
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-016-1804-9

Other articles of this Issue 1/2016

BMC Health Services Research 1/2016 Go to the issue

Research article

Effect of care management program structure on implementation: a normalization process theory analysis

Study protocol

Pragmatic cluster randomised trial of a free telephone-based health coaching program to support women in managing weight gain during pregnancy: the Get Healthy in Pregnancy Trial

Research article

Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study

Research article

Assessment of the contribution of morbidity and mortality conferences to quality and safety improvement: a survey of participants’ perceptions

Research article

Resource allocation and the burden of co-morbidities among patients diagnosed with chronic obstructive pulmonary disease: an observational cohort study from Danish general practice

Research article

The impact of user fees on health services utilization and infectious disease diagnoses in Neno District, Malawi: a longitudinal, quasi-experimental study